Literature DB >> 24975303

Prevalence of hepatitis B and C virus infections and their related risk factors in Libya: a national seroepidemiological survey.

A-N Elzouki, M-N Smeo, M Sammud, O Elahmer, M Daw, A Furarah, A Abudher, M K Mohamed.   

Abstract

A high prevalence of hepatitis B (HBV) and C virus (HCV) infections has been reported among specific patient groups in Libya; a survey was thus designed to determine the extent of the problem at the national level. A multi-stage sampling design covering all administrative areas of Libya was applied, covering > 65,000 individuals of all age groups. All subjects gave a blood sample and completed a questionnaire on demographic and risk behaviour data. The prevalence of HBV surface antigen (HBsAg) and anti-HCV were 2.2% and 1.3% respectively. The prevalence of anti-HCV increased with age, rising gradually after age 30 years, in contrast to a stable prevalence of HBsAg in all age groups 10+ years. Age-adjusted risk factors for HCV infection were previous hospitalization, surgical operations, previous blood transfusions and intravenous drug use; for HBV infection only family exposure or contact with HBV case were identified.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24975303

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  3 in total

1.  Hepatitis C Genotypes in Libya: Correlation with Patients' Characteristics, Level of Viremia, and Degree of Liver Fibrosis.

Authors:  Abdel-Naser Elzuoki; Islam Elzouki; Sabah Albarassi; Mohamed Gammo; Abdalla Burwaiss
Journal:  Oman Med J       Date:  2017-09

2.  Frequency of hepatitis B and C in health care providers at three referral hospitals in Libya.

Authors:  Abdel-Naser Elzouki; Rafat Lubbad; Islam Elzouki; Ahmed Elhaddad; Abdulfattah Ibrahim
Journal:  Pan Afr Med J       Date:  2020-11-03

3.  Expression of concern: Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population based survey.

Authors:  Philippa K Harris
Journal:  BMC Infect Dis       Date:  2015-02-19       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.